PharmaCyte Biotech Inc (PMCB)

[PINKribbon]

Obviously, the changes to the testings and processes during the period of time of their “Encapsulated cells producing cytochrome p450 and methods of use thereof" patent, there were “undoubtedly” more than one change made to processes which were outside of the patent scope.

Some of these changes, if not all, become “delayed priority claims”, hence their need to having filed the continuation.

It is not unusual, especially with companies having submitted a biologic patent, for these data changes to derail an existing patent where then a Continuation Application is filed.

And that is the case with PharmaCyte.

Their continuation filing is on the USPTO website for all to see.

USPTO: “...If a parent application is going to be abandoned, then any continuing application claiming its priority needs to be filed before the parent application is abandoned.”

This was done, and done successfully.

I TRUST WHAT I SEE ON THE USPTO WEBSITE.

I’m quite certain PharmaCyte, Austrianova, and the rest of the Team continue to work diligently to complete the work necessary to lift the hold.

Patience

Go Team PharmaCyte!!!